论文部分内容阅读
1目的 探讨降钙素 (CT)基因高度甲基化与恶性血液病预后的关系。 2方法 采用多聚酶链反应(PCR)技术 ,观察了 46例 CT基因高度甲基化阳性的恶性血液病病人完全缓解 (CR)后 CT基因的动态变化。 3结果 CT基因高度甲基化为阳性的 46例恶性血液病病人 ,CR后 30 d,有 32例病人仍为阳性 ,其余 14例转阴 ;CR后6 0 d,32例阳性病人中又有 5例转为阴性 ,而 14例阴性病人有 1例又转为阳性。随访发现 2 8例 CT基因高度甲基化阳性的病人有 19例在 CR后 6 0 d～ 1年内复发 ,复发率为 6 7.86 % ;18例阴性病人仅有 6例在同期内复发 ,复发率为 33.33% ,两组比较差异有极显著性 (χ2 =15 .84,P<0 .0 0 1)。 4结论 CT基因高度甲基化与恶性血液病病人的预后密切相关 ,且可作为预测疾病复发、指导临床治疗的可靠指标之一。
1 Objective To investigate the relationship between the hypermethylation of calcitonin (CT) gene and the prognosis of patients with hematologic malignancies. Methods The polymerase chain reaction (PCR) technique was used to detect the dynamic changes of CT genes in 46 patients with highly methylated hematologic malignancies after complete remission (CR). 3 Results CT gene hypermethylation was positive in 46 cases of hematological malignancies, 30 days after CR, 32 patients were still positive, and the remaining 14 negative; 60 days after CR, 32 cases of positive patients 5 cases turned negative, while 14 cases of negative patients turned positive again. A total of 28 patients with highly methylated CT were found to have relapsed within 6 days and 60 days after CR. The recurrence rate was 6 7.86%. Only 6 of 18 negative patients relapsed within the same period. The recurrence rate Was 33.33%. There was significant difference between the two groups (χ2 = 15.84, P <0.01). 4 Conclusions CT hypermethylation is closely related to the prognosis of patients with hematologic malignancies, and can be used as a reliable indicator of disease recurrence and clinical treatment.